Company Snapshot
- Ticker
- AMGN
- Name
- AMGN
- Sector
- None
- Currency
- 0
- Relative Volume
- None
- Market Cap
- 169652920000.000000
- Volume
- 2,075,731
- Avg Volume (3M)
- 2,502,400
AMGN
AMGN
Last update recent
315.34
+1.49
(+0.47%)
Market Cap
169652920000.000000
Dividend Yield
0.00%
1Y Return
None%
Beta
None
Price & Moving Averages
Interactive chart with SMA overlays and intraday breadth.
Profitability
- Revenue
- 35959000000.000000
- EPS
- 13.03
- Dividend / Share
- None
- Total Dividends
- $0.00
- Dividend Yield
- 2.97%
- Net Income
- 7005000000.000000
- Net Margin
- 19.48%
- Payout Ratio
- 72.03%
- Qtly Growth YoY
- None
Valuation & Quality
- P/E
- 24.22
- Forward P/E
- None
- P/S
- 4.72
- P/B
- 17.64
- Beta
- None
- Debt / Equity
- 5.67
- Current Ratio
- 1.28
- Return on Equity
- 0.73%
- Return on Assets
- 0.08%
Technicals & Returns
- Distance vs 200 DMA
- 7.72%
- 200 DMA
- 292.73
- Distance vs 50 DMA
- 0.81%
- 50 DMA
- 312.81
- Return 1Y
- None%
- Return YTD
- None%
- Beta (Trailing)
- None
- Relative Volume
- None
Factor Lens
Plot valuation, momentum, or volume trends.
Seasonal Performance
Company Overview
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic Read more
- Name
- AMGN
- Industry
- Drug Manufacturers - General
- CEO
- Mr. Robert A. Bradway
- Employees
- 26,700
- IPO Date
- 1983-06-17
- Phone
- 805 447 1000
- Address
- None
- Website
- https://www.amgen.com
Dividend Yield
0.00%
TTM Distributions
$0.00
Last Payout
2024-08-16 • $2.25
Latest News
Curated headlines from premium sources.
Amgen (AMGN) Rises As Market Takes a Dip: Key Facts
The latest trading day saw Amgen (AMGN) settling at $325.31, representing a +2.38% change from its previous close.
Argenx Halts Phase 3 Thyroid Eye Disease Trial, Peers Like Viridian Therapeutics To Benefit
Argenx discontinues its Phase 3 UplighTED trial in thyroid eye disease after an interim futility review, while analysts maintain confidence in Vyvgart's broade…
Amgen Inc. $AMGN Shares Sold by Corient Private Wealth LLC
Corient Private Wealth LLC reduced its stake in Amgen Inc. (NASDAQ: AMGN) by 2.2% in the second quarter, according to the company in its most recent disclosure…
30,728 Shares in Amgen Inc. $AMGN Acquired by Caldwell Trust Co
Caldwell Trust Co acquired a new stake in shares of Amgen Inc. (NASDAQ: AMGN) in the second quarter, according to the company in its most recent filing with th…
2 Dividend Stocks to Double Up on Right Now
These two pharmaceutical giants have faced -- or will soon face -- patent cliffs. Both are innovative drugmakers, which should allow them to overcome this issue.
Why Ditching Schwab U.S. Dividend Equity ETF In the AI Era Is a Mistake
The rapid rise of artificial intelligence (AI) has transformed the stock market in recent years, powering massive gains in technology giants and growth-oriente…